BioVie CEO Cuong Do on Parkinson's & Long COVID Trial Progress

Parkinson's Disease Trial Update

• 🚀 BioVie is making significant progress with its Parkinson's trial, aiming to be the first new treatment in over 50 years.
• 🤝 Support from foundations like the Michael J. Fox Foundation is helping to drive patient enrollment.
• 🗓️ The trial is expected to be fully enrolled by year-end, with top-line data anticipated by April or May of next year.
• 💡 The investigational therapy, Bezyisterum, aims to slow disease progression in newly diagnosed patients and improve muscle control when used alongside levodopa.

Long COVID Clinical Trials

• 🧠 17 million Americans suffer from Long COVID, experiencing debilitating symptoms like brain fog and fatigue.
• 🏥 BioVie's Long COVID trial is supported by major academic centers including Mayo Clinic, Mount Sinai, Yale, and UCSF.
• ⏳ Top-line data for the Long COVID trials is anticipated by mid-next year.
• 🎯 Bezyisterum is being investigated for its potential to help Long COVID patients by addressing chronic inflammation.

The Connection: TNF Alpha and Inflammation

• 🔗 The common link between Parkinson's and Long COVID is inflammation mediated by tumor necrosis factor alpha (TNF-α).
• ⚡ In Parkinson's, TNF-α contributes to insulin resistance and low dopamine levels, while in Long COVID, it's believed to be triggered by lingering viral proteins.
• 🔬 Blocking TNF-α with Bezyisterum is the therapeutic approach for both conditions, aiming to reverse insulin resistance and reduce inflammation.

Finding Trial Information

• 🌐 Potential patients can find comprehensive details about the ongoing clinical trials, including site locations, on BioVie's official website at biovipharma.com.
• 🖱️ Specific information is available under the 'Clinical Trials' section of the website.